首页> 外文OA文献 >233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

【2h】

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

机译：233tippembrolizumab（Pembro）或安慰剂添加到多西紫杉醇和泼尼松/泼尼松酮中，用于预先用下一代激素剂（NHAS）治疗的转移性阉割抗癌前列腺癌（MCRPC）：Keynote-921期III研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
相似文献
相关主题

著录项

作者
D.P. Petrylak; N.D. Shore; M. Bennamoun; R. Ratta; J.M. Piulats; B. Li; C. Schloss; K. Fizazi;
展开▼
作者单位

展开▼
年度 2020
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献

1. 343?Phase 3 study of pembrolizumab docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) pretreated with next-generation hormonal agents (NHAs) (KEYNOTE-921) [J] . Daniel Petrylak, Neal Shore, Mostefa Bennamoun, Journal for ImmunoTherapy of Cancer . 2020 ,第Suppla3期

机译：343？相3研究Pembrolizumab Docetaxel和泼尼松/泼尼松酮，用于用下一代激素剂（NHAS）预处理（Keynote-921）预处理的转移性阉割的前列腺癌（MCRPC）
2. 341?Phase 1b/2 study of BXCL701, an oral activator of the systemic innate immunity pathway, combined with pembrolizumab (pembro), in men with metastatic castration-resistant prostate cancer (mCRPC) [J] . Rahul Aggarwal, Dan Costin, Jingsong Zhang, Journal for ImmunoTherapy of Cancer . 2020 ,第Suppla3期

机译：341？1B / 2对BXCL701的研究，全身先天免疫途径的口服活化剂，与Pembrozumab（Pembro）联合，在具有转移性阉割的前列腺癌的男性中（MCRPC）
3. Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 [J] . Fizazi Karim, Jones Robert, Oudard Stephane, Journal of Clinical Oncology . 2015 ,第7期

机译：多西他赛治疗期间或之后进展为转移性去势抵抗的前列腺癌患者的三期随机双盲多中心试验，比较Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松
4. Phase III Randomized Double-Blind Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5 [O] . Karim Fizazi, Robert Jones, Stephane Oudard, -1

机译：多西他赛治疗期间或之后进展为转移性去势抵抗的前列腺癌患者的三期随机双盲多中心试验比较Orteronel（TAK-700）+泼尼松与安慰剂+泼尼松
5. KEYNOTE-921: Phase III study of pembrolizumab (pembro) plus docetaxel and prednisone for enzalutamide (enza)- or abiraterone (abi)-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) [O] . D.P. Petrylak, B. Li, C. Schloss, 2019

机译：Keynote-921：Pembrolizumab（PEMBRO）的第III阶段研究加入多西甲基（苯甲酸丁醛（ENZA） - 或ABIRATERONE（ABI） - 预期患者（PTS），具有转移性阉割的前列腺癌（MCRPC）

233TiP Pembrolizumab (pembro) or placebo added to docetaxel and prednisone/prednisolone for metastatic castration-resistant prostate cancer (mCRPC) previously treated with next-generation hormonal agents (NHAs): KEYNOTE-921 phase III study

著录项

相似文献

相关主题

期刊订阅